stockrowDenali Therapeutics Inc.
DNLI Healthcare Biotechnology
Denali Therapeutics Inc.’s revenue for fiscal 2023 (year ended December 2023) was $330.5 million, up 204.7% from fiscal 2022.
- Revenue
- −94.0%
- EPS
- +150.3%
- Free cash flow
- −11.8%
- Total debt
- −1.89%
Quarter to September 2026, against a year earlier
Follow DNLI
Alert me
Denali Therapeutics Inc. (DNLI) EBITDA
Denali Therapeutics Inc.'s EBITDA for fiscal 2025 was −$554.4M, compared with −$514.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$524.5M. Over the past ten years it has ranged from −$554.4M (fiscal 2025) to $71.3M (fiscal 2020) — the current reading is the lowest in ten years. Denali Therapeutics Inc. ranks 579th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$554.4M | — |
| FY2024 | −$514.7M | — |
| FY2023 | −$223.9M | — |
| FY2022 | −$332.0M | — |
| FY2021 | −$278.4M | — |
| FY2020 | $71.3M | — |
| FY2019 | −$210.2M | — |
| FY2018 | −$41.7M | — |
| FY2017 | −$86.3M | — |
| FY2016 | −$85.7M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | −$124.2M | — |
| Jun 2026 | −$128.4M | — |
| Mar 2026 | −$135.8M | — |
| Dec 2025 | −$136.1M | — |
| 35 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ELVN Enliven Therapeutics, Inc. compare | −$123.8M |
| CELC Celcuity, Inc. compare | −$204.0M |
| IDYA IDEAYA Biosciences, Inc. compare | −$463.5M |
| VRDN Viridian Therapeutics, Inc. compare | −$474.6M |
| DNLI Denali Therapeutics Inc. | −$524.5M |
| DYN Dyne Therapeutics, Inc. compare | −$536.1M |
| VKTX Viking Therapeutics, Inc. compare | −$652.8M |
| TARS Tarsus Pharmaceuticals, Inc. compare | −$695.5M |
| TLX Telix Pharmaceuticals Limited compare | — |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on DNLI
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement